Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment

Thrombosis Research
J BorawskiM Mysliwiec


Correction of uremic platelet serotonin (5-HT) storage pool deficiency is one of the very early hemostatic effects of erythropoietin (Epo) therapy. In this work, platelet 5-HT with relation to primary hemostasis was studied in 15 hemodialysis patients treated with Epo for 8 months. Moreover, effects of ketanserin, a blocker of platelet and vascular smooth muscle cell 5-HT2A receptors, in these patients were followed. The parameters studied were compared with relevant values in healthy controls and in hemodialysis patients not treated with Epo, and remeasured in the long-term Epo patients after a 14-day oral ketanserin trial. Platelet 5-HT content in the eighth month of Epo therapy was not different from the one in untreated patients. Ristocetin- and collagen-induced platelet aggregation were enhanced in comparison with both control groups, as opposed to unaltered response to ADP and arachidonic acid. Fibrinogen concentration was lower than in the untreated group. An inverse correlation between ADP-induced platelet aggregation and the skin bleeding time (r=-0.536, p<0.05) and a positive one between the former and platelet 5-HT (r=0.644, p<0.01) were found. Platelet count correlated positively with both platelet 5-HT (r=0.823, p<...Continue Reading


Apr 1, 1971·British Journal of Pharmacology·J A AngusM H Maguire
May 3, 2001·Blood Reviews·D MateiV J Marder


Jan 1, 1991·Journal of Cardiovascular Pharmacology·F De Clerck
Jan 1, 1991·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·I C MacdougallJ D Williams
Jan 1, 1990·Cardiovascular Drugs and Therapy·A E Doyle
Feb 1, 1985·The Journal of Pharmacy and Pharmacology·P S WilsoncroftP K Moore
Aug 17, 1984·European Journal of Pharmacology·W BuczkoG De Gaetano
Apr 1, 1995·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·J E TaylorW K Stewart
Jun 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·J D EmeryJ B Lawrence
Mar 1, 1995·Trends in Pharmacological Sciences·G BaxterT Blackburn
Feb 20, 1993·Lancet·D StenverJ Mehlsen
Oct 1, 1995·Journal of Cardiovascular Pharmacology·J BorawskiM Mysliwiec
Jul 15, 1996·Thrombosis Research·D PawlakM Mysliwiec
Jan 1, 1996·American Journal of Nephrology·J BorawskiM Mysliwiec
Mar 1, 1996·Journal of Cardiovascular Pharmacology·R A GeerlingR L Marquet
Apr 1, 1964·Clinica Chimica Acta; International Journal of Clinical Chemistry·G W ASHCROFTE J MACDOUGALL

Related Concepts

Epoetin Alfa
Platelet Aggregation Measurement
Depressed - Symptom
Arachidonic Acid
HTR2A wt Allele
Fibrinogen Assay
Erythropoietin Measurement

Related Feeds


Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.